Abstract: Disclosed are a compression mechanism and a scroll compressor. The compression mechanism comprises an orbiting scroll and a non-orbiting scroll comprising a non-orbiting scroll end plate and forms a series of fluid chambers comprising an intermediate compression chamber. An exhaust communication space is provided on the second side of the non-orbiting scroll end plate, and the non-orbiting scroll end plate is provided with a pressure relief port which makes at least one intermediate compression chamber be in selective fluid communication with the exhaust communication space. An end plate surface on the first side of the non-orbiting scroll end plate is provided with an exhaust groove which is in communication with the pressure relief port, the pressure relief port can be in fluid communication with the at least one intermediate compression chamber through the exhaust groove.

Abstract: A main bearing housing assembly for a scroll compressor and a scroll compressor having the main bearing housing assembly. The main bearing housing assembly comprises: a main bearing housing; and a thrust plates, the thrust plate being provided at the top of the main bearing housing, and comprising a thrust surface located at the top and in surface contact with the bottom end surface of a scroll assembly of the scroll compressor; the thrust plate comprises: at least one oil inlet hole; a closed oil chamber, the closed oil chamber being formed in the thrust plate; and at least one oil outlet hole, the opening of the at least one oil outlet hole being exposed to the thrust surface; and the at least one oil inlet hole is in communication with the at least one oil outlet hole by means of the closed oil chamber.

Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.

Abstract: Disclosed are a compression mechanism and a scroll compressor. The compression mechanism comprises an orbiting scroll and a non-orbiting scroll comprising a non-orbiting scroll end plate and forms a series of fluid chambers comprising an intermediate compression chamber. An exhaust communication space is provided on the second side of the non-orbiting scroll end plate, and the non-orbiting scroll end plate is provided with a pressure relief port which makes at least one intermediate compression chamber be in selective fluid communication with the exhaust communication space. An end plate surface on the first side of the non-orbiting scroll end plate is provided with an exhaust groove which is in communication with the pressure relief port, the pressure relief port can be in fluid communication with the at least one intermediate compression chamber through the exhaust groove.

Abstract: The disclosure discloses a genetically engineered strain for producing porcine myoglobin and fermentation and purification thereof, and belongs to the technical field of genetic engineering. The disclosure realizes efficient secretion and expression of porcine myoglobin by integrating the gene of porcine myoglobin in P. pastoris. On this basis, optimization of the medium and culture conditions of recombinant P. pastoris can significantly increase the titer of porcine myoglobin, so that the titer can reach 285.42 mg/L under fermenter conditions. In addition, by creatively adding different concentrations of ammonium sulfate to fermentation broth step by step, the purity of myoglobin obtained by final concentration is up to 88.0%, and the purification rate is up to 66.1%.

Abstract: A main bearing housing assembly for a scroll compressor and a scroll compressor having the main bearing housing assembly. The main bearing housing assembly comprises: a main bearing housing; and a thrust plates, the thrust plate being provided at the top of the main bearing housing, and comprising a thrust surface located at the top and in surface contact with the bottom end surface of a scroll assembly of the scroll compressor; the thrust plate comprises: at least one oil inlet hole; a closed oil chamber, the closed oil chamber being formed in the thrust plate; and at least one oil outlet hole, the opening of the at least one oil outlet hole being exposed to the thrust surface; and the at least one oil inlet hole is in communication with the at least one oil outlet hole by means of the closed oil chamber.

Abstract: The disclosure discloses a genetically engineered strain for producing porcine myoglobin and fermentation and purification thereof, and belongs to the technical field of genetic engineering. The disclosure realizes efficient secretion and expression of porcine myoglobin by integrating the gene of porcine myoglobin in P. pastoris. On this basis, optimization of the medium and culture conditions of recombinant P. pastoris can significantly increase the titer of porcine myoglobin, so that the titer can reach 285.42 mg/L under fermenter conditions. In addition, by creatively adding different concentrations of ammonium sulfate to fermentation broth step by step, the purity of myoglobin obtained by final concentration is up to 88.0%, and the purification rate is up to 66.1%.

Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.

Abstract: The subject invention pertains to compositions and methods of eradicating biofilms and/or inhibiting the formation of a biofilms or fouling by non-biofilm forming organisms using elasnin-based compositions. In certain embodiments, the elasnin can be combined with antimicrobial compounds and/or traditional coating ingredients.

Abstract: Pharmacological compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof are described. Further, methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof are provided.

Abstract: Certain embodiments of the invention pertain to pharmaceutical compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof. Certain other embodiments of the invention pertain to methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof.

Abstract: A novel Tistrella mobilis strain having Accession Deposit Number NRRL B-50531 is provided. A method of producing a didemnin precursor, didemnin or didemnin derivative by using the Tistrella mobilis strain, and the therapeutic composition comprising at least one didemnin or didemnin derivative produced from the strain or modified strain thereof are also provided.

Abstract: A novel Tistrella mobilis strain having Accession Deposit Number NRRL B-50531 is provided. A method of producing a didemnin precursor, didemnin or didemnin derivative by using the Tistrella mobilis strain, and the therapeutic composition comprising at least one didemnin or didemnin derivative produced from the strain or modified strain thereof are also provided.

Abstract: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2,5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.

Abstract: An anti-fouling agent derived by culturing Vibrio alginolyticus in a suitable aqueous solution as well as a newly isolated strain of V. alginolyticus (DSM 15590) for producing the anti-fouting agent. The anti-fouling agent can be used as a component to produce other anti-fouling compositions, Depending on the use, the anti-fouling agent derived from V. alginolyricus may be use directly, or subject to further purification.

Abstract: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2, 5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.

Abstract: An anti-fouling agent derived by culturing Vibrio alginolyticus in an aqueous solution suitable for growth thereof is described. The anti-fouling agent is produced and secreted by Vibrio alginolyticus, which can then be used as a component to produce other anti-fouling compositions. Depending on the use, the anti-fouling agent derived from V. alginolyticus may be used directly, or subject to further purification. A newly isolated strain of V. alginolyticus (DSM 15590) is also disclosed.